Department of Diagnostic Imaging & Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
World Neurosurg. 2024 Jun;186:e495-e505. doi: 10.1016/j.wneu.2024.03.164. Epub 2024 Apr 5.
To clarify the relationships between C-methionine (MET) positron emission tomography (PET) metrics and the histology, genetics, and prognosis of adult-type diffuse glioma (ADG) based on the World Health Organization (WHO) 2021 classification.
A total of 125 newly diagnosed patients with ADG were enrolled. We compared the maximum standardized uptake value (SUVmax), tumor-to-normal background ratio (TNR), metabolic tumor volume (MTV), and total lesion methionine uptake (TLMU) to the histology and genetics of the patients with ADG. We also evaluated the prognoses of the 93 surgically treated patients.
The patients with isocitrate dehydrogenase wild ADG showed significantly higher MET-PET metrics (P < 0.05 for all parameters), significantly shorter overall survival and progression-free survival (P < 0.0001 for both) than those of the patients with isocitrate dehydrogenase mutant (IDHm) ADG. In the IDHm ADG group, the SUVmax, MTV, and TLMU values were significantly higher in patients with IDHm grade (G) 4 astrocytoma than patients with IDHm G2/3 astrocytoma (P < 0.05 for all), but not than patients with G2-3 oligodendroglioma. The progression-free survival was significantly shorter in the patients with G4 astrocytoma versus the patients with G2/3 astrocytoma and G3 oligodendroglioma (P < 0.05 for both). The SUVmax and TNR values were significantly higher in recurrent patients than nonrecurrent patients (P < 0.01 for both), but no significant differences were found in MTV or TLMU values.
MET-PET metrics well reflect the histological subtype, WHO grade and prognosis of ADG based on the 2021 WHO classification, with the exception of oligodendroglial tumors. Volumetric parameters were not significantly associated with recurrence, unlike the SUVmax and TNR.
根据 2021 年世界卫生组织(WHO)分类,明确 C-蛋氨酸(MET)正电子发射断层扫描(PET)指标与成人弥漫性胶质瘤(ADG)的组织学、遗传学和预后之间的关系。
共纳入 125 例新诊断的 ADG 患者。我们比较了最大标准化摄取值(SUVmax)、肿瘤与正常背景比(TNR)、代谢肿瘤体积(MTV)和总病变蛋氨酸摄取(TLMU)与 ADG 患者的组织学和遗传学的关系。我们还评估了 93 例接受手术治疗的患者的预后。
异柠檬酸脱氢酶野生型 ADG 患者的 MET-PET 指标明显更高(所有参数 P<0.05),总生存期和无进展生存期明显更短(均 P<0.0001)。与异柠檬酸脱氢酶突变型(IDHm)ADG 患者相比。在 IDHm ADG 组中,IDHm 级(G)4 星形细胞瘤患者的 SUVmax、MTV 和 TLMU 值明显高于 IDHm G2/3 星形细胞瘤患者(所有 P<0.05),但与 G2-3 少突胶质细胞瘤患者无差异。与 IDHm G2/3 星形细胞瘤和 G3 少突胶质细胞瘤患者相比,G4 星形细胞瘤患者的无进展生存期明显缩短(均 P<0.05)。与非复发性患者相比,复发性患者的 SUVmax 和 TNR 值明显更高(均 P<0.01),但 MTV 或 TLMU 值无显著差异。
MET-PET 指标很好地反映了 2021 年 WHO 分类中 ADG 的组织学亚型、WHO 分级和预后,除了少突胶质细胞瘤。与 SUVmax 和 TNR 不同,体积参数与复发无显著相关性。